Education
About Us
Working with TipRanks
Follow Us
Arrowhead Pharmaceuticals (ARWR)
NASDAQ:ARWR
ARWR Stock Chart & Stats
Day’s Range― - ―
52-Week Range$14.23 - $30.41
Previous CloseN/A
Volume680.40K
Average Volume (3M)1.53M
Market Cap
$2.03B
Enterprise Value$2.67B
Total Cash (Recent Filing)$53.89M
Total Debt (Recent Filing)$115.86M
Price to Earnings (P/E)―
Beta1.98
Next Earnings
May 08, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.15
Shares Outstanding137,317,370
10 Day Avg. Volume1,785,787
30 Day Avg. Volume1,533,153
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)746.50
Price to Cash Flow (P/CF)-3.20
P/FCF Ratio0.00
Enterprise Value/Market Cap1.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit751.83
Enterprise Value/Ebitda-4.60
Forecast
1Y Price Target
$40.60Price Target Upside161.94% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
---
Bulls Say, Bears Say
Bulls Say
Efficacy And SafetyARO-C3 showed a mean reduction in serum AH50 and Wieslab AP, further indicating a competitive profile.
Financial PerformanceThe collaboration with SRPT has closed, and ARWR will receive $825mm, consisting of $500mm cash and $325mm as an equity investment priced at a 35% premium to 30-day volume weighted average price.
Product DevelopmentPositive Phase 1/2 data with ARO-C3 support confidence in the blockbuster potential of Arrowhead's complement disease franchise.
Bears Say
Capital RequirementsARWR continues to see rationale for a CVOT (CAPITAN trial in mixed dyslipidemia) but awaits substantial further capital to initiate the study.
Market RisksRisks include clinical development risk, competitor risk, novel modality risk, commercialization risk, reimbursement risk, pricing risk, business development risk, capital market and dilution risk, and disruptions to clinical trials.
---
Ownership Overview
4.15% Insiders
16.19% Mutual Funds
22.41% Other Institutional Investors
31.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ARWR FAQ
What was Arrowhead Pharmaceuticals’s price range in the past 12 months?
Arrowhead Pharmaceuticals lowest stock price was $14.22 and its highest was $30.41 in the past 12 months.
What is Arrowhead Pharmaceuticals’s market cap?
Arrowhead Pharmaceuticals’s market cap is $2.03B.
When is Arrowhead Pharmaceuticals’s upcoming earnings report date?
Arrowhead Pharmaceuticals’s upcoming earnings report date is May 08, 2025 which is in 44 days.
How were Arrowhead Pharmaceuticals’s earnings last quarter?
Arrowhead Pharmaceuticals released its earnings results on Feb 10, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$0.476 by -$0.914.
Is Arrowhead Pharmaceuticals overvalued?
According to Wall Street analysts Arrowhead Pharmaceuticals’s price is currently Undervalued.
Does Arrowhead Pharmaceuticals pay dividends?
Arrowhead Pharmaceuticals does not currently pay dividends.
What is Arrowhead Pharmaceuticals’s EPS estimate?
Arrowhead Pharmaceuticals’s EPS estimate is -0.2.
How many shares outstanding does Arrowhead Pharmaceuticals have?
Arrowhead Pharmaceuticals has 137,317,370 shares outstanding.
What happened to Arrowhead Pharmaceuticals’s price movement after its last earnings report?
Arrowhead Pharmaceuticals reported an EPS of -$1.39 in its last earnings report, missing expectations of -$0.476. Following the earnings report the stock price went down -5.171%.
Which hedge fund is a major shareholder of Arrowhead Pharmaceuticals?
Currently, no hedge funds are holding shares in ARWR
---
Arrowhead Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$40.60 (161.94% Upside)
$40.60 (161.94% Upside)
Blogger Sentiment
Bullish
ARWR Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 956.8K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $971.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.57%
12-Months-Change
Fundamentals
Return on Equity
-600.68%
Trailing 12-Months
Asset Growth
61.86%
Trailing 12-Months
Company Description
Arrowhead Pharmaceuticals
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
---
ARWR Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with major highlights such as the closing of a significant deal with Sarepta Therapeutics, upcoming launches, and strong pipeline advancements in obesity and CNS. However, increased operating expenses and a higher net loss were noted as lowlights, with some uncertainties regarding the timing of the CVOT for plozasiran.Read More>---
ARWR Stock 12 Month Forecast
Average Price Target
$40.60
▲(161.94% Upside)
Technical Analysis
Alnylam Pharma
―
Ionis Pharmaceuticals
―
Sarepta Therapeutics
―
Arcturus Therapeutics
―
Moderna
―
Best Analysts Covering ARWR
1 Year
1 Year Success Rate
19/40 ratings generated profit
1 Year Average Return
+27.30%
reiterated a buy rating last month
Copying Keay Nakae's trades and holding each position for 1 Year would result in 47.50% of your transactions generating a profit, with an average return of +27.30% per trade.
---